In Q4 2025, Phathom generated net revenues of 57584000, with operating expenses of 55865000 and a net loss of 21148000. Non-GAAP adjusted net loss improved significantly to 5735000, reflecting lower operating expenses and continued VOQUEZNA growth.

Phathom Pharmaceuticals delivered strong sequential revenue growth in Q2 2025, driven by the continued commercial launch of VOQUEZNA products. The company reported net revenues of $39.5 million, a substantial increase from the previous year, and reduced its net loss. Strategic cost reductions and a refined commercial strategy focusing on high-value prescribers are positioning the company for profitability in 2026.

Phathom Pharmaceuticals reported a significant increase in net revenues for Q1 2025 driven by the continued launch of VOQUEZNA products. Despite seasonal headwinds, filled prescriptions for VOQUEZNA increased sequentially. The company also announced strategic cost reductions and leadership changes aimed at achieving profitability from operations, excluding stock-based compensation, in 2026.

Phathom Pharmaceuticals reported strong third quarter results, driven by the commercial launch of VOQUEZNA. Net revenues reached $16.4 million, and there was significant growth in prescriptions and the prescriber base. The company's cash and cash equivalents totaled $334.7 million as of September 30, 2024.

Phathom Pharmaceuticals reported net revenues of $7.3 million for the second quarter 2024, a greater than 280% increase compared to the first quarter 2024. The company also highlighted the FDA approval of VOQUEZNA 10 mg tablets for heartburn associated with Non-Erosive GERD and the expansion of commercial coverage to over 116 million U.S. lives.

Phathom Pharmaceuticals reported $1.9 million in net revenues for the first quarter of 2024, marking the first full quarter of VOQUEZNA launch. The company saw over 17,500 total prescriptions dispensed, a 361% increase since the last quarterly report. Cigna Healthcare added VOQUEZNA tablets to its formularies, broadening coverage to approximately 48% of U.S. commercial lives.

Phathom Pharmaceuticals reported Q4 2023 financial results, highlighted by the launch of VOQUEZNA and net revenues of $0.7 million from its sales. The company also secured expanded commercial coverage and strengthened its financial position with an expanded term loan facility.

Phathom Pharmaceuticals reported a net loss of $43.2 million for the third quarter of 2023. The company highlighted the FDA approval of VOQUEZNA for Erosive GERD and the submission of an NDA for vonoprazan as a daily treatment for Non-Erosive GERD.

Phathom Pharmaceuticals reported a net loss of $41.0 million for the second quarter of 2023. The company made significant progress on regulatory submissions for VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, completed a public offering resulting in $141.4 million in net proceeds, and is preparing for commercial launches in Q4 2023.

Phathom Pharmaceuticals reported a net loss of $37.8 million for Q1 2023, with operating expenses decreasing due to cost control measures. The company is on track to resubmit its Erosive GERD NDA and anticipates a potential commercial launch in Q4 2023. They believe they have sufficient capital to fund operations through the end of 2024.

Phathom Pharmaceuticals reported a net loss of $55.0 million for the fourth quarter ended December 31, 2022, compared to a net loss of $35.8 million for the fourth quarter of 2021. Research and development expenses for the fourth quarter 2022 were $15.9 million, and general and administrative expenses were $30.7 million. Cash and cash equivalents were $155.4 million as of December 31, 2022.

Phathom Pharmaceuticals reported a net loss of $51.1 million for the third quarter of 2022. The company completed enrollment in its Phase 3 NERD daily dosing trial and secured a commitment for up to an additional $40 million under a revenue interest financing agreement.

Phathom Pharmaceuticals reported a net loss of $50.9 million for the second quarter of 2022. The company is preparing for a combined full commercial launch of both H. pylori and EE in the first quarter of 2023.

Phathom Pharmaceuticals reported a net loss of $40.7 million for the first quarter of 2022. The company received FDA approval for VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK and strengthened its balance sheet with a revenue interest financing agreement.

Phathom Pharmaceuticals reported a net loss of $35.8 million for the fourth quarter of 2021, driven by a net loss from operations of $33.0 million. Research and development expenses decreased to $13.5 million, while general and administrative expenses increased to $19.5 million.

Phathom Pharmaceuticals reported a net loss of $36.7 million for the third quarter of 2021. The FDA accepted NDAs for two vonoprazan-based treatment regimens for H. pylori infection, and positive Phase 3 trial results for vonoprazan in erosive esophagitis were reported.

Phathom Pharmaceuticals reported a net loss of $36.6 million for the second quarter of 2021. The company is progressing with its GERD development programs and expects to submit NDAs to the FDA for H. pylori infection treatments in September 2021.

Phathom Pharmaceuticals reported a net loss of $34.8 million for the first quarter of 2021. The company highlighted positive Phase 3 trial results for vonoprazan in H. pylori infection and the initiation of a Phase 2 trial for NERD.

Phathom Pharmaceuticals reported a net loss of $53.7 million for the fourth quarter of 2020, driven by operating expenses, including research and development, and general and administrative costs. The company highlighted the completion of patient enrollment in Phase 3 trials for vonoprazan and the planned expansion of its development program.

Phathom Pharmaceuticals reported a net loss of $34.1 million for the third quarter of 2020, compared to a net loss of $68.1 million for the third quarter of 2019. Research and development expenses increased to $25.8 million, while general and administrative expenses increased to $7.1 million. As of September 30, 2020, cash and cash equivalents were $226.4 million.

Phathom Pharmaceuticals reported a net loss of $21.1 million for the second quarter of 2020. The company resumed patient screening and enrollment in Phase 3 trials for vonoprazan and continued to build its organization. R&D and G&A expenses increased due to clinical trial costs and the buildout of administrative and commercial functions. Cash and cash equivalents were $247.3 million as of June 30, 2020.

Phathom Pharmaceuticals reported a net loss of $20.1 million for the first quarter of 2020, which included non-cash charges related to stock-based compensation of $0.6 million and a change in fair value of warrant liabilities of ($0.1) million. The company's research and development expenses increased to $15.9 million, and general and administrative expenses increased to $4.5 million. As of March 31, 2020, cash and cash equivalents were $256.7 million.

Phathom Pharmaceuticals reported a net loss of $98 million for Q4 2019, which included non-cash charges. The company initiated Phase 3 clinical trials for Vonoprazan and paused new patient randomization due to the COVID-19 pandemic. They also completed an initial public offering and appointed Mark Stenhouse to the Board of Directors.